Analytical Data
-
Gene name
PDGFA
- Application
-
Alternative Names
Platelet-derived growth factor subunit A;PDGF subunit A;PDGF-1;Platelet-derived growth factor A chain;Platelet-derived growth factor alpha polypeptide; PDGFA;PDGF1
-
Species
Human
-
Source
E. coli
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P04085
-
Expression Region
87-211aa
-
Molecular Weight
14.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Coagulation Factor II, also known as prothrombin, is a critical protein in the blood coagulation cascade, playing a pivotal role in hemostasis by facilitating the conversion of fibrinogen to fibrin during the clotting process. Deficiencies or mutations in Factor II can lead to abnormal bleeding disorders, emphasizing the need for detailed understanding and potential therapeutic interventions. Recombinant Factor II proteins have emerged as promising solutions, offering advantages in safety and efficacy compared to traditional plasma-derived products. The ability to produce Factor II through recombinant techniques allows for the generation of a more consistent and purer product, which is crucial for clinical applications. Moreover, advances in biotechnology have led to the development of various recombinant forms of Factor II, enabling targeted modifications to enhance stability, activity, and patient-specific therapeutic needs. Research into recombinant Factor II not only aims to improve treatment for patients with coagulation disorders but also to explore its potential in novel therapeutic applications, such as in anticoagulation therapies and tissue engineering. As such, the study of recombinant Coagulation Factor II represents a significant frontier in both hematology and biopharmaceutical development, with the potential to transform treatment approaches for coagulation-related diseases.
